These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2891021)

  • 21. Clinical applications of alpha 1-receptor blockade: terazosin in the management of hypertension. Introduction.
    Rosenthal J; Kyncl JJ
    J Clin Pharmacol; 1993 Sep; 33(9):866-7. PubMed ID: 7901240
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of terazosin in the treatment of essential hypertension in blacks.
    Luther RR; Klepper MJ; Maurath CJ; Glassman HN; Achari R; Laddu AR
    J Hum Hypertens; 1990 Apr; 4(2):151-3. PubMed ID: 1971027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Progress in the studies of alpha1-adrenoceptor blocker for concurrent benign prostatic hyperplasia and hypertension].
    Yang MG; Zhao XK
    Zhonghua Nan Ke Xue; 2007 Sep; 13(9):830-4. PubMed ID: 17929564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical settings for selective alpha-adrenergic receptor inhibition: rationale and management strategies. Proceedings of a symposium. Naples, Florida, October 13 to 16, 1988.
    Am J Med; 1989 Aug; 87(2A):1S-66S. PubMed ID: 2569821
    [No Abstract]   [Full Text] [Related]  

  • 26. Hypertension, coronary risk and alpha-blockade.
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():1-65. PubMed ID: 1979818
    [No Abstract]   [Full Text] [Related]  

  • 27. [Hepatotoxicity induced by terazosin].
    Fernández Salazar L; Palencia García A
    Med Clin (Barc); 2003 Feb; 120(3):118. PubMed ID: 12605736
    [No Abstract]   [Full Text] [Related]  

  • 28. [The effect of terazosin and nitrendipine on blood insulin, glucose and lipid in SHR rats].
    Wang W
    Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Aug; 21(4):234-5. PubMed ID: 7910793
    [No Abstract]   [Full Text] [Related]  

  • 29. Prolonged penile erection association with terazosin in a cervical spinal cord injury patient.
    Vaidyanathan S; Soni BM; Singh G; Sett P; Krishnan KR
    Spinal Cord; 1998 Nov; 36(11):805. PubMed ID: 9848493
    [No Abstract]   [Full Text] [Related]  

  • 30. Terazosin: a new alpha adrenoceptor blocking drug.
    Achari R; Laddu A
    J Clin Pharmacol; 1992 Jun; 32(6):520-3. PubMed ID: 1353083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [An open randomized comparative trial of efficacy and safety of selective alpha-adrenoblocker setegis (terazosin) in therapy of patients with chronic bacterial prostatitis].
    Trapeznikova MF; Morozov AP; Dutov VV; Urenkov SB; Pozdniakov KV; Bychkova NV
    Urologiia; 2007; (2):33-7. PubMed ID: 17578197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.
    Cohen JD
    Am Heart J; 1991 Sep; 122(3 Pt 2):919-25. PubMed ID: 1678923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic expulsive treatment of ureteral calculi.
    Beach MA; Mauro LS
    Ann Pharmacother; 2006; 40(7-8):1361-8. PubMed ID: 16849614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention].
    Yang C; Li YL; Fang J; Zhang X; Liu HP; Qin XH; Xu XP
    Zhonghua Nan Ke Xue; 2009 May; 15(5):441-4. PubMed ID: 19514558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
    Beretta-Piccoli C; Ferrier C; Weidmann P
    J Hypertens Suppl; 1985 Dec; 3(3):S231-4. PubMed ID: 2908818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
    Luther RR; Glassman HN; Estep CB; Schmitz PJ; Horton JK; Jordan DC
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):237S-240S. PubMed ID: 2901267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pressure and metabolic effects of terazosin in essential hypertension].
    Valle R; Semplicini A; Serena L; Gebbin A; Fontebasso A; Gerardi G; De Toni R; Pessina AC
    Cardiologia; 1994 Jun; 39(6):421-4. PubMed ID: 7923256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of alpha 1-blockers in combination therapy for hypertension.
    Zusman RM
    Int J Clin Pract; 2000; 54(1):36-40. PubMed ID: 10750258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of terazocin on hypertensive patients].
    Liu G
    Zhonghua Xin Xue Guan Bing Za Zhi; 1990 Oct; 18(5):271-2. PubMed ID: 1982259
    [No Abstract]   [Full Text] [Related]  

  • 40. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension.
    Ferrier C; Beretta-Piccoli C; Weidmann P; Mordasini R
    Clin Pharmacol Ther; 1986 Nov; 40(5):525-30. PubMed ID: 2876796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.